There is an urgent need for novel treatment options for people living with rare diseases, but carrying out clinical research in this field is notoriously difficult. As Clinical Trials Day approaches, Cezary Statuch, Head of Medical Affairs International and Japan at Alexion Pharmaceuticals, highlights how adopting patient-centric approaches can help overcome the unique challenges of designing, recruiting and conducting clinical trials for rare diseases.
Rare diseases affect up to 36 million people in the EU, and as many as 400 million people globally.1,2 they are often progressive, life-limiting and incurable. Half of people diagnosed with a rare disease are children, 30 percent of whom die before they reach the age of five.3
Significant unmet needs
The path to diagnosis of a rare disease is complex, taking on average five to eight years from the onset of symptoms before a patient receives an accurate diagnosis.4 In some countries, limited access to diagnostic tools and specialised care, combined with low levels of awareness, can mean this takes even longer.
Even with a diagnosis, patients continue to face barriers to care. With no meaningful treatment options for 90 percent of the 10,000 known rare diseases, it is clear there is an essential and urgent need for innovation in the field.5,6
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Clinical trials are essential for the safety and efficacy of novel therapies to be established. They are the cornerstone of the regulatory review process and play a critical role in how the value of a new therapy is assessed by health systems and payers. Yet, there are inherent challenges in rare disease clinical research.
Engaging with patients and caregivers is key to addressing these challenges. Gaining a deep understanding of rare diseases and how they impact peoples’ lives is critical for designing and executing meaningful trials that meet the unique needs of the patient population.
Deep understanding of rare diseases is key to progressing innovation
Clinical research is always complex, but there are a host of additional complexities that need to be navigated in rare disease research – primarily stemming from the fact that these diseases are often not well understood, with small patient populations.
There are often significant gaps in medical and scientific information regarding rare diseases, including a lack of detailed knowledge of their natural history. Furthermore, the sources of information that are available for more common conditions – assays, endpoints, patient registries, regulatory precedent – often don’t exist.
Gaining a deep understanding of rare diseases and how they impact peoples’ lives is critical for designing and executing meaningful trials that meet the unique needs of the patient population.
This can make establishing meaningful endpoints for clinical trials problematic. For example, without understanding the natural trajectory of disease progression without medical intervention, or against the standard of care, for comparison, it can be challenging to determine the effect of a novel therapy. There is often no precedent or established framework to follow.
Thus, developing a deep understanding of rare diseases and combining this with the agility to innovate and adopt new R&D approaches is essential to drive innovation forward.
Harnessing new technology
Applying artificial intelligence (AI) and machine learning can increase rare disease understanding, with powerful tools emerging to potentially help shorten the time to diagnosis and identify and validate potential therapeutic targets more efficiently. Given that 80 percent of rare diseases have a genetic origin,7 these tools may also aid the development of gene and cell therapies, which are rapidly emerging as a promising new route for delivering the breakthroughs patients so urgently need.
Navigating the complexities of small patient populations
Compared to more common diseases, rare-disease patient populations are small and dispersed. This creates unique barriers to recruiting and retaining patients for trials. In addition, the specificity of inclusion criteria can further narrow the pool of eligible patients.
As a result, enrolling patients in clinical trials is seen by pharmaceutical industry leaders as one of the biggest barriers to the development of potentially transformative medicines for rare diseases. In fact, one-quarter of rare disease trials between 2016 and 2020 were terminated due to low accrual rates.8
Standard clinical trial designs are not always appropriate for diseases with small patient populations to generate adequate safety and efficacy data. Alternative approaches offer the potential to inform the efficacy and safety of rare disease treatments by reducing the size or number of trials, while also reducing development programme time. Innovative trial designs can include complex adaptive designs, enrichment trials, multi-arm multistage trials, seamless trials, and N-of-1 (single-patient) studies.
When designing trials for small populations, experience in navigating the complexities of rare diseases and learning from the wider research community is vital. It is also important to consider the impact of alternative clinical trial designs on regulatory decision making and how collaboration between researchers and regulators for innovative trial designs has the potential to contribute to accelerating the progress of novel therapies towards patients.
Patients must be our guide
Researchers have a profound responsibility to ensure clinical trials meet the needs of the patient population and are scientifically rigorous and clinically meaningful. Only by designing trials around patients can the best results be achieved for clinical research programmes, and ultimately for delivering innovations to patients.
Unlike in other therapeutic areas, the departure of just one patient from a rare disease trial can have a significant impact on the conduct and outcome of that trial. Direct feedback from individual patients and caregivers can help shape trial protocols to ensure clinical trials are accessible and conducive to long-term participation; for example, by developing tools and resources to help patients understand the expectations of the study and navigate trial sites. These insights can also inform how trial outputs are defined and evaluated, ensuring they reflect meaningful outcomes.
Every day counts; every patient counts
Digital health technologies (DHTs) have significant potential for enabling clinical research to focus on patients’ needs.
Digital health technologies (DHTs) can accelerate clinical trial timelines
As well as improving the patient experience of clinical trials, DHTs can accelerate clinical trial timelines. The average length of time from the start of clinical testing to approval of a novel treatment is 7.1 years.9 For patients living with serious, progressive rare diseases with no approved treatment options, every day counts. Exploring the potential of DHTs to reduce the amount of time it takes for innovations to reach patients should be a priority for the research community.
DHTs can also enable clinical researchers to decentralise clinical trials, giving the potential to increase the geographic and socioeconomic diversity of the clinical trial population. Notably, they could help to expand the global clinical trial footprint for rare diseases beyond Europe and the US, into Latin America, Asia and the Middle East where rare disease ecosystems are now emerging and developing rapidly.
Complexity demands collaboration
With rare diseases being inherently unique and not well understood, this creates a complex research environment. As a result, developing and enabling access to transformative medicines for people living with rare diseases requires collaboration with patients, healthcare professionals, advocates, investigators, pharmacists, health authorities, policymakers and others. It also requires the commitment, tenacity and ingenuity to close the knowledge gaps in rare diseases; deepen our medical and scientific understanding of these conditions; tackle the issue of delayed diagnosis; and establish healthcare policies and systems that can enable innovation to thrive and overcome health inequalities.
From whichever angle each of us comes to the challenge of clinical research in rare diseases, there is a shared recognition that patients are urgently waiting. Delivering effective, meaningful treatments to patients faster is the priority. By working together and putting patients at the centre of clinical research, we can accelerate towards this.
About the author
Cezary Statuch is currently the Head of Medical Affairs, International and Japan at Alexion, a global biopharmaceutical company focused on developing life-changing therapies for people living with rare diseases. He has spent more than 30 years working in the pharmaceutical industry, holding positions in clinical research operations, global drug development and medical affairs.
Cezary is actively engaged in the training and education of physicians in the healthcare industry across many emerging and established markets. He is a founding member of the China Medical Affairs Network, and is also a member of the Executive Committee of the Medical Affairs Professional Society.
Wakap, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. European Journal of Human Genetics (2020) 28:165–173. https://doi.org/10.1038/s41431-019-0508-0
Kaufmann, et al. From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research. Orphanet Journal of Rare Diseases (2018) 13:196. https://doi.org/10.1186/s13023-018-0936-x
Elliott ZT, et al. Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers. Clinics and Practice. 2022 Aug 31;12(5):692–700.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.